Cory Abate-Shen

Cory Abate-Shen

Titles

Michael and Stella Chernow Professor of Urological Oncology
Interim Director, Herbert Irving Comprehensive Cancer Center

Affiliations

Department of Systems Biology
Department of Pathology and Cell Biology
Center for Multiscale Analysis of Genomic and Cellular Networks (MAGNet)

Administrative Coordinator:
Margaret Loughlin
ml3153@columbia.edu


Cory Abate-Shen is a professor in the Department of Urology and Department of Pathology and Cell Biology, the Michael and Stella Chernow Chair of Urological Oncology, and an associate director of the Herbert Irving Cancer Center. She is investigating the molecular mechanisms of homeobox genes in development and cancer. Her laboratory has provided groundbreaking insights on the molecular bases of how homeoproteins achieve target gene recognition in vivo. She has also developed mouse models of prostate cancer that have been widely used to investigate the molecular bases of prostate tumorigenesis and as preclinical models for intervention and therapy. She has been the recipient of several awards, including a Sinsheimer Scholar Award, an NSF Young Investigator Award, and the Women in Cell Biology Junior Award from the American Society for Cell Biology. She is currently the principal investigator on five federal grants including an NCI consortium grant on Mouse Models of Human Cancer. In addition, she has received funding from several other sources including the March of Dimes, the New Jersey Commission on Cancer Research and the Gustave and Louise Pfeiffer Research Foundation. She has recently been named an American Association of Cancer Research Professor.


Education History

PhD, Cornell University Medical College (Neurobiology)


Selected Publications

Wang J, Kumar R, Biggs VJ, Lee H, Chen Y, Kagey MH, Young RA, Abate-Shen C. The Msx1 homeoprotein recruits Polycomb to the nuclear periphery during development. Dev Cell. 2011 Sep 13;21(3):575-88.

Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010 Sep 15;24(18):1967-2000.

Wang X, Kruithof-deJulio M, Economides KD, Walker D, Yu H, Halili MV, Hu Y-P, Price SM, Abate-Shen C, Shen MM. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009 Sep 24;461(7263):495-500.

Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, Vickers AJ, Gerald WL, Abate-Shen C. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 2008 Apr 1;68(7):2132-44.

Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting Akt/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008 118(9):3051-3064. 


Address

Herbert Irving Comprehensive Cancer Center
1130 Saint Nicholas Avenue
New York, NY 10032


Lab Staff

Research Staff

Research Staff

Greg Hamilton

Research Technician

Research Technician

Research Staff

Jingqiang Wang

Associate Research Scientist

Associate Research Scientist

Postdoctoral Scientists

Postdoctoral Scientists

Alvaro Aytes

Postdoctoral Research Scientist

Postdoctoral Research Scientist

Postdoctoral Scientists

Aditya Dutta

Postdoctoral Research Scientist

Postdoctoral Research Scientist

Postdoctoral Scientists

Nicolas Floc'h

Postdoctoral Research Scientist

Postdoctoral Research Scientist

Postdoctoral Scientists

Clementine Le Magnen

Postdoctoral Research Scientist

Postdoctoral Research Scientist

Postdoctoral Scientists

Tomasz Owczarek

Postdoctoral Research Scientist

Postdoctoral Research Scientist

Undergraduate Students

Undergraduate Students

Daniel Chester

Undergraduate Student

Undergraduate Student


News

Synergy between Two Genes Drives Aggressive Prostate Cancer
Using a new computational method for comparing regulatory networks in human cancer cells with those in a mouse model, researchers found that FOXM1 and CENPF together drive the most lethal prostate tumors.
Biomarker Identified for Predicting Prostate Cancer Aggressiveness
Measurements of the expression levels of three genes associated with aging can be used to better assess which patients with indolent prostate cancer require treatment.
Study Supports Cell-of-Origin Model of Prostate Cancer Heterogeneity
The cell-of-origin model suggests that the aggressiveness of a tumor may result from the type of cell from which it arises. A new study has identified molecular signatures that hold potential as biomarkers of specific prostate cancer subtypes.